Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Metastat, Inc. (MTST : OTC)
 
 • Company Description   
MetaStat, Inc. is a life science company focused on understanding and treating systemic metastasis. The Company's portfolio is comprised of two diagnostic assets - MetaSite(TM) and MenaCalc(TM) and a therapeutic platform - MenaBloc(TM). Its MetaSite Breast(TM) and MenaCalc(TM) diagnostic product lines are designed to predict the probability of cancer metastasizing and MenaBloc therapeutics to reduce or eliminate metastasis. MetaStat, Inc. is headquartered in Montclair, New Jersey.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $ Daily Weekly Monthly
20 Day Moving Average: shares
Shares Outstanding: (millions)
Market Capitalization: $ (millions)
Beta:
52 Week High: $0.03
52 Week Low: $0.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week % %
12 Week % %
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
27 DRYDOCK AVE. 2ND FLOOR
-
BOSTON,MA 02210
USA
ph: 617-531-6500
fax: -
rpierce@metastat.com http://www.metastat.com
 
 • General Corporate Information   
Officers
Douglas A. Hamilton - President; Chief Executive Officer and Director
Jerome B. Zeldis - Chairman
Daniel H. Schneiderman - Vice President
Paul Billings - Director
Johan M. (Thijs) Spoor - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 59140A203
SIC: 2834
Fiscal Year
Fiscal Year End: February
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding:
Most Recent Split Date: 10.00 (0.07:1)
Beta:
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: %
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
02/28/22 - -
11/30/21 - -
08/31/21 - -
ROA
02/28/22 - -
11/30/21 - -
08/31/21 - -
Current Ratio
02/28/22 - -
11/30/21 - -
08/31/21 - -
Quick Ratio
02/28/22 - -
11/30/21 - -
08/31/21 - -
Operating Margin
02/28/22 - -
11/30/21 - -
08/31/21 - -
Net Margin
02/28/22 - -
11/30/21 - -
08/31/21 - -
Pre-Tax Margin
02/28/22 - -
11/30/21 - -
08/31/21 - -
Book Value
02/28/22 - -
11/30/21 - -
08/31/21 - -
Inventory Turnover
02/28/22 - -
11/30/21 - -
08/31/21 - -
Debt-to-Equity
02/28/22 - -
11/30/21 - -
08/31/21 - -
Debt-to-Capital
02/28/22 - -
11/30/21 - -
08/31/21 - -
 

Powered by Zacks Investment Research ©